Literature DB >> 2681762

Regulation of plasminogen activators and their inhibitors in rheumatic diseases: new understanding and the potential for new directions.

D A Hart1, M J Fritzler.   

Abstract

Over the past several years there has been a rapid expansion in our understanding of the fibrinolytic system. This includes knowledge of the components, availability of recombinant reagents and a better understanding of the regulation of fibrinolysis in health and disease. Disturbances in the regulation of the balance between fibrin deposition and removal have been implicated in a number of inflammatory diseases including certain rheumatic diseases. This overview summarizes our knowledge of the components of the fibrinolytic system, discusses evidence for their involvement in certain rheumatic diseases and speculates on their possible use in disease assessment and treatment.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2681762

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  6 in total

1.  Imbalance of tissue-type plasminogen activator (t-PA) and its specific inhibitor (PAI-1) in patients with rheumatoid arthritis associated with disease activity.

Authors:  L T Kopeikina; E F Kamper; V Koutsoukos; Y Bassiakos; I Stavridis
Journal:  Clin Rheumatol       Date:  1997-05       Impact factor: 2.980

2.  Tissue plasminogen activator (tPA) inhibits human neutrophil superoxide anion production in vitro.

Authors:  K A Stringer; J Lindenfeld; A J Repine; Z Cohen; J E Repine
Journal:  Inflammation       Date:  1997-02       Impact factor: 4.092

3.  Management of Raynaud's Phenomenon in the Patient with Connective Tissue Disease.

Authors:  Soumya Chatterjee
Journal:  Curr Treat Options Cardiovasc Med       Date:  2010-04

4.  Derangement of hemostasis in rheumatoid arthritis: association with demographic, inflammatory and metabolic factors.

Authors:  Theodoros Dimitroulas; Karen M J Douglas; Vasileios F Panoulas; Tracey Toms; Jacqueline P Smith; Gareth J Treharne; Peter Nightingale; James Hodson; George D Kitas
Journal:  Clin Rheumatol       Date:  2013-05-15       Impact factor: 2.980

5.  Tissue plasminogen activator, plasminogen activator inhibitor-1 and von Willebrand factor in rheumatoid arthritis.

Authors:  S Wållberg-Jonsson; G H Dahlén; T K Nilsson; M Rånby; S Rantapää-Dahlqvist
Journal:  Clin Rheumatol       Date:  1993-09       Impact factor: 2.980

6.  Comparative study of tetranectin levels in serum and synovial fluid of patients with rheumatoid arthritis, seronegative spondylarthritis and osteoarthritis.

Authors:  E F Kamper; L T Kopeikina; P Trontzas; N C Kyriazis; G Vaiopoulos; J Stavridis
Journal:  Clin Rheumatol       Date:  1998       Impact factor: 2.980

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.